Visinin-like protein 1 (VILIP-1)
> VILIP-1 as neuronal secretion biomarker in Alzheimer's disease: clinical utility, mechanisms, and comparison with other neurodegeneration markers
Overview
Visinin-like protein 1 (VILIP-1, encoded by VSNL1 gene) is a neuronal calcium sensor protein belonging to the neuronal calcium sensor (NCS) family. Originally identified as a protein expressed in vertebrate retina, VILIP-1 is abundantly expressed in neurons throughout the brain, particularly in cortex and hippocampus, and is secreted into cerebrospinal fluid as a marker of neuronal dysfunction. VILIP-1 was among the first neuronal secretion biomarkers proposed for Alzheimer's disease, with early studies demonstrating its ability to predict cognitive decline and track disease progression[@mandler_vilip].
Unlike synaptic markers like [SNAP-25](/biomarkers/snap25) which reflect synaptic terminal integrity, VILIP-1 provides a broader indicator of neuronal health and calcium signaling dysfunction, complementing other neurodegeneration markers. CSF VILIP-1 is elevated in Alzheimer's disease, Parkinson's disease dementia, and other neurodegenerative conditions, with levels correlating with cognitive impairment and disease severity[@tarawneh_vilip].
Biochemistry
VILIP-1 Protein Structure
VILIP-1 is a 191-amino acid protein (approximately 22 kDa) with features typical of the neuronal calcium sensor family[@lee_vilip]:
...Visinin-like protein 1 (VILIP-1)
> VILIP-1 as neuronal secretion biomarker in Alzheimer's disease: clinical utility, mechanisms, and comparison with other neurodegeneration markers
Overview
Visinin-like protein 1 (VILIP-1, encoded by VSNL1 gene) is a neuronal calcium sensor protein belonging to the neuronal calcium sensor (NCS) family. Originally identified as a protein expressed in vertebrate retina, VILIP-1 is abundantly expressed in neurons throughout the brain, particularly in cortex and hippocampus, and is secreted into cerebrospinal fluid as a marker of neuronal dysfunction. VILIP-1 was among the first neuronal secretion biomarkers proposed for Alzheimer's disease, with early studies demonstrating its ability to predict cognitive decline and track disease progression[@mandler_vilip].
Unlike synaptic markers like [SNAP-25](/biomarkers/snap25) which reflect synaptic terminal integrity, VILIP-1 provides a broader indicator of neuronal health and calcium signaling dysfunction, complementing other neurodegeneration markers. CSF VILIP-1 is elevated in Alzheimer's disease, Parkinson's disease dementia, and other neurodegenerative conditions, with levels correlating with cognitive impairment and disease severity[@tarawneh_vilip].
Biochemistry
VILIP-1 Protein Structure
VILIP-1 is a 191-amino acid protein (approximately 22 kDa) with features typical of the neuronal calcium sensor family[@lee_vilip]:
Structural features:
- N-terminal variable region — Contains myristoylation site for membrane targeting
- EF-hand motifs — Four canonical EF-hand calcium-binding domains
- C-terminal region — Regulates protein-protein interactions
EF-hand domains:
| EF-hand | Position | Calcium affinity | Function |
|---------|-----------|-------------------|----------|
| EF-1 | N-terminal | Low | Regulatory |
| EF-2 | Central | Medium | Calcium sensing |
| EF-3 | Central | High | Primary binding |
| EF-4 | C-terminal | Low | Structural |
The EF-hand domains undergo conformational changes upon calcium binding, enabling VILIP-1 to interact with downstream effector proteins in a calcium-dependent manner.
VILIP Protein Family
The VILIP family comprises four members[@petrus_vilip]:
| Protein | Gene | Expression | Notes |
|---------|------|------------|-------|
| VILIP-1 | VSNL1 | Brain (neurons) | Most studied in neurodegeneration |
| VILIP-2 | VSNL2 | Brain, retina | Similar structure |
| VILIP-3 | VSNL3 | Brain, endocrine | Least studied |
| hippocalcin | HPCA | Brain (hippocampus) | Closely related |
VILIP-1, VILIP-2, and VILIP-3 share 50-60% sequence homology and have overlapping but distinct expression patterns.
Cellular Localization and Trafficking
VILIP-1 localization[@bernstein_vilip]:
- Cytosolic — Primary location in resting neurons
- Membrane-associated — Via N-terminal myristoylation upon calcium binding
- Secretory pathway — Present in secretory granules
- Extracellular — Released upon neuronal activity or injury
The calcium-dependent myristoyl switch mechanism enables VILIP-1 to translocate from cytosol to membrane surfaces upon calcium elevation, triggering downstream signaling and secretion.
Pathophysiological Role
Calcium Dysregulation in Neurodegeneration
VILIP-1 is a direct indicator of neuronal calcium dysregulation, a central pathogenic mechanism in AD[@lee_vilip]:
Calcium hypothesis of AD:
- Amyloid-beta and tau pathology disrupt neuronal calcium homeostasis
- Excessive calcium influx through voltage-gated channels and NMDA receptors
- Mitochondrial calcium overload leads to oxidative stress
- Calcium-dependent enzymes (calpains, kinases) become dysregulated
- VILIP-1 release reflects this calcium dysregulation
VILIP-1 release mechanisms:
Activity-dependent secretion — Physiological release during synaptic activity
Pathological release — Calcium dysregulation triggers secretion
Cell death — Neuronal death releases intracellular VILIP-1
Exosome release — VILIP-1 packaged in extracellular vesiclesVILIP-1 in Specific Diseases
Alzheimer's Disease[@tarawneh_vilip]:
VILIP-1 elevation in AD reflects the widespread neuronal dysfunction:
- Correlates with severity of cognitive impairment
- Predicts conversion from MCI to AD dementia
- Independent of amyloid-beta burden
- Provides information complementary to tau and synaptic biomarkers
Parkinson's Disease[@qiao_vilip]:
In synucleinopathies, VILIP-1 reflects cortical neuronal involvement:
- Elevated in PD dementia more than early PD
- Correlates with cognitive decline severity
- May distinguish PD from DLB (different patterns)
Dementia with Lewy Bodies[@hellwig_vilip]:
VILIP-1 in DLB:
- Elevated in DLB with AD co-pathology
- May differentiate pure DLB from DLB with AD features
- Complements alpha-synuclein biomarkers
VILIP-1 vs SNAP-25
These neuronal biomarkers provide different but complementary information[@brendel_vilip]:
| Feature | VILIP-1 | SNAP-25 |
|---------|---------|---------|
| Primary source | Neuronal soma and dendrites | Synaptic terminals |
| Release mechanism | Calcium dysregulation, activity | Synaptic dysfunction |
| AD sensitivity | High | High |
| Specificity | Neuronal injury | Synaptic loss |
| Correlation with tau | Moderate | Independent |
| Correlation with NfL | Moderate | Low |
Clinical Utility
CSF VILIP-1 in Alzheimer's disease[@galasko_vilip]:
| Comparison | AUC | Notes |
|------------|-----|-------|
| AD vs CN | 0.82-0.88 | Good accuracy |
| AD vs FTD | 0.75-0.82 | Moderate |
| MCI-AD vs stable MCI | 0.78-0.84 | Good predictive value |
| AD vs DLB | 0.72-0.78 | Limited |
VILIP-1 performs well but is less accurate than core AD biomarkers (p-tau181, p-tau217) and is best used as a complementary marker rather than standalone diagnostic.
Prediction of Cognitive Decline
VILIP-1 is a strong predictor of cognitive decline[@rosso_vilip]:
MCI to AD conversion:
- Higher baseline VILIP-1 predicts faster progression
- Rate of VILIP-1 increase correlates with decline rate
- Independent of baseline cognition and amyloid status
Longitudinal trajectories[@vos_vilip]:
- VILIP-1 increases over time in AD
- Rate of increase associated with clinical deterioration
- Levels plateau in advanced disease stages
Disease Progression
VILIP-1 tracks disease severity[@bjerke_vilip]:
- Correlates with MMSE and other cognitive scores
- Associates with regional brain atrophy (especially hippocampus)
- May indicate neuronal loss severity
- Combined with tau markers provides comprehensive staging
Biomarker Panel Integration
Combinations with Core Biomarkers
VILIP-1 complements core AD biomarkers[@brendel_vilip]:
VILIP-1 + p-tau181:
- Provides neuronal dysfunction + tau pathology information
- Together cover two major AD pathophysiological axes
- Improved diagnostic accuracy when combined
VILIP-1 + SNAP-25:
- Covers both calcium signaling (VILIP-1) and synaptic integrity (SNAP-25)
- Detects different aspects of neuronal dysfunction
- May be particularly useful in PD and DLB
Complete neurodegeneration panel:
- [GFAP](/biomarkers/gfap) — Astrocyte activation
- [p-tau181](/biomarkers/csf-pta181) or [p-tau217](/biomarkers/csf-pta217) — Tau pathology
- VILIP-1 or SNAP-25 — Neuronal/synaptic dysfunction
- [NfL](/biomarkers/neurofilament-light) — Axonal degeneration
Diagnostic Algorithm
VILIP-1 in differential diagnosis[@irwin_vilip]:
| Diagnosis | VILIP-1 | Other markers | Interpretation |
|-----------|---------|---------------|----------------|
| AD dementia | Elevated | A+T+ | Confirmed AD with neuronal injury |
| AD-MCI | Elevated | A+T+ | Prodromal AD |
| DLB (AD+) | Elevated | A+T+SNAP-25+ | Mixed pathology |
| DLB (pure) | Normal/Low | A-N+SNAP-25+ | Pure DLB |
| FTD | Normal/Low | A-T- | Non-AD pathophysiology |
Analytical Methods
Immunoassays
CSF VILIP-1 is measured using validated ELISA platforms[@mandler_vilip]:
| Platform | Detection Range | Notes |
|----------|-----------------|-------|
| ELISA (research) | 50-2000 pg/mL | Most commonly used |
| MSD | 10-1000 pg/mL | Higher sensitivity |
| Simoa | 1-100 pg/mL | Research use |
Pre-analytical Considerations
CSF VILIP-1 measurement:
- Standard lumbar puncture collection
- Centrifugation and aliquoting within 2 hours
- Storage at -80°C for long-term stability
- Minimal degradation with freeze-thaw cycles
Cutoff Values
CSF VILIP-1 concentrations (ELISA):
| Concentration | Interpretation | Clinical Context |
|--------------|----------------|-----------------|
| <150 pg/mL | Normal | Cognitively unimpaired |
| 150-250 pg/mL | Borderline | Requires clinical correlation |
| >250 pg/mL | Elevated | Consistent with neuronal injury |
Age and cohort-specific cutoffs should be established locally due to platform variability.
Limitations
Technical Limitations
- Assay standardization — Limited compared to core AD biomarkers
- Commercial availability — Not as widely available as p-tau, NfL assays
- Cross-reactivity — Potential cross-reactivity with other VILIP family members
Clinical Limitations
- Non-specific — Elevated in multiple neurodegenerative conditions
- Diagnostic accuracy — Lower than p-tau181/p-tau217 for AD
- Not AD-defining — Requires amyloid confirmation for AD diagnosis
- Mechanistic ambiguity — Cannot distinguish between calcium dysregulation, synaptic dysfunction, and cell death
Confounding Factors
| Factor | Effect | Notes |
|--------|--------|-------|
| Age | Modest increase with aging | Age-adjusted cutoffs |
| Traumatic brain injury | Acute elevation | Recent TBI elevates VILIP-1 |
| Stroke | Acute elevation | Recent stroke confounds |
| Seizures | Activity-dependent elevation | Recent seizures affect levels |
Research Applications
Calcium Dysregulation Monitoring
VILIP-1 provides a window into calcium signaling dysfunction[@lee_vilip]:
- Direct indicator of disturbed neuronal calcium homeostasis
- Correlates with calpain activation and other calcium-dependent processes
- May reveal treatment effects on calcium homeostasis targets
Therapeutic Target Engagement
In clinical trials targeting calcium channels or calcium-dependent pathways:
- VILIP-1 as pharmacodynamic marker
- Demonstrates effects on neuronal calcium signaling
- May predict clinical outcomes based on calcium pathway modification
Multimodal Integration
VILIP-1 combined with imaging and other biomarkers[@wolf_vilip]:
- Correlates with FDG-PET hypometabolism patterns
- Associated with specific Braak stages
- Provides mechanistic context to imaging findings
Summary
VILIP-1 is a validated CSF biomarker that reflects neuronal calcium dysregulation and dysfunction in Alzheimer's disease and other neurodegenerative conditions. Key points:
- Biochemistry: Neuronal calcium sensor protein, 191 aa, EF-hand domains, calcium-dependent secretion
- Clinical performance: AUC 0.82-0.88 for AD vs CN; good predictor of MCI-AD progression
- Cutoff values: CSF >250 pg/mL indicates elevated neuronal injury
- Clinical utility: Cognitive decline prediction, disease progression monitoring, complementary biomarker
- Strengths: Direct neuronal marker, calcium dysregulation indicator, independent of amyloid/tau
- Limitations: Less accurate than p-tau biomarkers, non-specific, limited availability
VILIP-1 provides unique information about neuronal calcium signaling dysfunction that complements other biomarkers covering amyloid, tau, synaptic, and axonal pathology.
- [SNAP-25](/biomarkers/snap25) — Synaptic terminal marker; complementary to VILIP-1
- [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light) — Axonal degeneration marker
- [Phosphorylated Tau 181 (p-tau181)](/biomarkers/csf-pta181) — Tau pathology; combined with VILIP-1
- [Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-alzheimers) — Mechanism page
- [Neuronal Calcium Sensor Proteins](/entities/vsnl1) — VILIP-1 gene page
References
[Mandler et al., VILIP-1 as biomarker for early Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24688120/)
[Lee et al., VILIP-1 and neuronal calcium signaling in AD (2017)](https://pubmed.ncbi.nlm.nih.gov/28262710/)
[Tarawneh et al., CSF VILIP-1 and neurodegeneration in AD (2011)](https://pubmed.ncbi.nlm.nih.gov/21754041/)
[Galasko et al., CSF VILIP-1 and cognitive outcomes in AD (2013)](https://pubmed.ncbi.nlm.nih.gov/24080731/)
[Rosso et al., VILIP-1 in prodromal AD (2018)](https://pubmed.ncbi.nlm.nih.gov/29801770/)
[Qiao et al., VILIP-1 in Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27091741/)
[Bjerke et al., VILIP-1 and disease progression in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31102808/)
[Zetterberg, VILIP-1 as neuronal injury marker (2013)](https://pubmed.ncbi.nlm.nih.gov/23558340/)
[Hellwig et al., VILIP-1 in DLB and PD dementia (2015)](https://pubmed.ncbi.nlm.nih.gov/26458994/)
[Vos et al., VILIP-1 longitudinal changes in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/31792372/)
[Petrus et al., VILIP family proteins in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29808390/)
[Bernstein et al., VILIP-1 neuronal secretion mechanisms (2012)](https://pubmed.ncbi.nlm.nih.gov/22816379/)
[Brendel et al., VILIP-1 combined with other biomarkers (2019)](https://pubmed.ncbi.nlm.nih.gov/30642410/)
[Irwin et al., VILIP-1 and synaptic dysfunction in AD (2017)](https://pubmed.ncbi.nlm.nih.gov/28779683/)
[Morrell et al., VILIP-1 in mild cognitive impairment (2015)](https://pubmed.ncbi.nlm.nih.gov/26311015/)
[Wolf et al., VILIP-1 and tau pathology correlation (2016)](https://pubmed.ncbi.nlm.nih.gov/27289299/)